Ann Elizabeth Kingston

Title: Ann Elizabeth Kingston: Innovator in Medicinal Chemistry

Introduction

Ann Elizabeth Kingston is a prominent inventor based in Indianapolis, IN (US). She has made significant contributions to the field of medicinal chemistry, particularly in the development of selective mGluR1 antagonists. Her work has implications for the treatment of various medical conditions, showcasing her dedication to advancing healthcare through innovation.

Latest Patents

Ann Elizabeth Kingston holds a patent for the "Use of n-substituted (3,6-dihydro)-2h-1,2-oxazine derivatives as selective mGluR1 antagonists." This patent describes a compound of formula (I) that includes various substituents, which can be used in the manufacture of a medicament for treating conditions that require the administration of a selective mGluR1 antagonist. This innovative approach highlights her expertise in creating effective pharmaceutical solutions.

Career Highlights

Throughout her career, Ann has been associated with Eli Lilly and Company, a leading pharmaceutical firm known for its commitment to research and development. Her work at Eli Lilly has allowed her to contribute to groundbreaking advancements in drug development and therapeutic applications.

Collaborations

Ann has collaborated with notable colleagues, including Barry P. Clark and John Richard Harris. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to successful outcomes in their projects.

Conclusion

Ann Elizabeth Kingston's contributions to medicinal chemistry and her innovative patent work exemplify her commitment to improving healthcare solutions. Her collaborations and career at Eli Lilly and Company further underscore her impact in the field.